The antibiotic G418 was shown to be an effective inhibitor of vaccinia virus replication when an appropriate concentration of it was added to cell monolayers 48 h before infection. Genetic engineering techniques were used in concert with DNA transfection protocols to construct vaccinia virus recombinants containing the neomycin resistance gene (neo) from transposon TnS. These recombinants contained the neo gene linked in either the correct or incorrect orientation relative to the vaccinia virus 7.5-kilodalton gene promoter which is expressed constitutively throughout the course of infection. The vaccinia virus recombinant containing the chimeric neo gene in the proper orientation was able to grow and form plaques in the presence of G418, whereas both the wild-type and the recombinant virus with the neo gene in the opposite polarity were inhibited by more than 98%. The effect of G418 on virus growth may be mediated at least in part by selective inhibition of the synthesis of a subset of late viral proteins. These results are discussed with reference to using this system, the conferral of resistance to G418 with neo as a positive selectable marker, to facilitate constructing vaccinia virus recombinants which contain foreign genes of interest.
The antibiotic G418 was shown to be an effective inhibitor of vaccinia virus replication when an appropriate concentration of it was added to cell monolayers 48 h before infection. Genetic engineering techniques were used in concert with DNA transfection protocols to construct vaccinia virus recombinants containing the neomycin resistance gene (neo) from transposon TnS. These recombinants contained the neo gene linked in either the correct or incorrect orientation relative to the vaccinia virus 7.5-kilodalton gene promoter which is expressed constitutively throughout the course of infection. The vaccinia virus recombinant containing the chimeric neo gene in the proper orientation was able to grow and form plaques in the presence of G418, whereas both the wild-type and the recombinant virus with the neo gene in the opposite polarity were inhibited by more than 98%. The effect of G418 on virus growth may be mediated at least in part by selective inhibition of the synthesis of a subset of late viral proteins. These results are discussed with reference to using this system, the conferral of resistance to G418 with neo as a positive selectable marker, to facilitate constructing vaccinia virus recombinants which contain foreign genes of interest.
The use of cloning and expression vectors to study and experimentally manipulate individual genes independently of their normal resident environment has become a central and vital theme in molecular genetics. Due to a number of unique biological attributes, vaccinia virus (VV) would seem to offer an ideal system for such studies (12) . A number of laboratories have demonstrated the feasibility of this approach by constructing recombinant VV strains which contain and express heterologous viral and cellular antigens (13, 15, 16) . Such hybrid strains may prove useful in the preparation of vaccines against a variety of human and animal diseases.
Unfortunately the current methods used to construct VV recombinants are slow, time-consuming, and expensive and do not facilitate genetic engineering of the foreign DNA insert. These drawbacks have thus far retarded the development of VV as a general eucaryotic expression vector. The chief limitation of this system stems from the fact that the methods used to detect and isolate VV recombinants of interest rely on unsophisticated screening procedures (20) . One major improvement has been provided by Mackett et al., who developed a VV insertion vector which inserts foreign genes into the middle of the VV thymidine kinase (tk) gene (11) . This results in functional inactivation of tk activity and converts the recombinant virus to a tk-phenotype. In principle, it should be possible to select recombinants metabolically with bromodeoxyuridine. However, the spontaneous rate of tk-mutants arising in the virus population is quite high, on the order of 10-3 to 10-4, so that recombinant VV still makes up only a fraction of the total tk-population (D. E. Hruby, unpublished data). This is particularly troublesome if one is attempting to insert a large foreign gene which will be rescued at a low frequency. Thus, although the use of bromodeoxyuridine is certainly a useful enrichment technique, it does not provide a direct selection for recombinants. These problems could be circumvented if meth-ods were developed to employ dominant selectable markers for isolating VV recombinants.
An appropriate strategy might be the construction of tandem plasmid insertion vectors with a selectable marker linked to a foreign gene of interest. This would consist of a VV promoter (P1) linked to a polylinker region for the insertion of foreign genes, and a second VV promoter (P2) linked to a selectable marker, with the entire tandem arrangement embedded in VV DNA sequences sufficient to catalyze recombination into a nonessential region of the viral genome. Such a plasmid could be used to insert the tandem genes into the VV genome. Recombinants could then be selected directly by using biochemical agents.
There are a number of positive selection schemes which could potentially be adapted to the VV system, but the two with the greatest promise would seem to be selection of the tk+ phenotype with methotrexate (21) and of the Neor phenotype with G418 (18) . Methotrexate has previously been used to select VV recombinants with a tk+ phenotype that resulted from the insertion of a functional viral tk gene into a VV tk-mutant (21) . In analogy to selecting for tk-VV, it might be anticipated that the number of tk+ revertants would be equal to or greater than the number of tk+ VV arising from recombination. This problem could be circumvented by using a VV mutant containing a deletion in the tk region (11) . An alternative approach would be the use of G418. The synthetic antibiotic G418, which is an effective inhibitor of protein synthesis in both eucaryotic and procaryotic systems, has been used as a selective agent for transformants that have taken up and are expressing the bacterial neomycin resistance gene, neo (18 the neomycin resistance gene from Tn5 (3). Plasmids were obtained with the gene in both orientations and were designated pVV:NEb (correct orientation) and pVV:lEO (opposite orientation).
Marker rescue. The insertion of the neo gene into the VV genome was performed essentially by the method described elsewhere (submitted for publication). The recombinant plasmids were coprecipitated with wild-type VV DNA and carrier salmon sperm DNA by using calcium orthophosphate (6) . The precipitated DNAs were transfected into Ltk-cells 3 h after they were infected with VV at a multiplicity of 0.05 PFU/cell. The infected-cell monolayers were shocked with glycerol for 40 s to facilitate DNA uptake (10) and then incubated at 37°C for 48 h. The progeny of this initial marker rescue step were then passaged through Ltk-cells in the presence of bromodeoxyuridine (25 ,ug/ml) to amplify the number of tk-VV in the population. Recombinant VV containing the neo gene were then detected by plaque hybridization with a nick-translated BglII-BamHI neo DNA fragment as the probe (3). Individual recombinant plaques were punched out from replica nitrocellulose filters and inoculated into 24-well dishes of BSC-40 cells. After 48 h, cell extracts were prepared by trypsinizing the infected cells. A portion of each extract was subjected to dot blot analysis (10) to confirm that VV containing the neo gene were present. Virus from extracts scored as positive were then subjected to an additional round of plaque purification and grown on a larger scale.
DNA analysis. DNA was extracted and purified from cytoplasmic extracts of BSC-40 cells infected at a multiplicity of 10 PFU/cell with putative VV recombinants (submitted for publication). The DNA was digested with various restriction endonucleases, and the fragments were resolved by electrophoresis in 0.8% agarose gels (14) . After being stained with 0.5 ,ug of ethidium bromide per ml, the gels were photographed, blotted onto nitrocellulose, and hybridized with appropriate nick-translated DNA fragments as probes (17) . In all cases, wild-type VV DNA was run as a control. Reference was made to previously published restriction maps of VV DNA (4), as well as to unpublished data from our own laboratory, to determine the genomic structure of the VV recombinants. MOL. CELL. BIOL. (1, 140 Ci/mmol; New England Nuclear Corp.) at the indicated times postinfection or continuously labeled by having 5 jCi of radioactive label per ml present throughout the infection. The radioactively labeled infected cells were harvested and collected by centrifugation. The pellets were suspended in 100 ,ul of 1 mM Tris-hydrochloride (pH 9), and a small portion was used to determine the hot trichloroacetic acid-precipitable counts. Equivalent amounts of radioactively labeled cell lysates were then analyzed on 12% sodium dodecyl sulfate-polyacrylamide slab gels (19) . The gels were then impregnated with 2,5-diphenyloxazole and fluorographed at -70°C on Kodak XAR-5 film (1).
RESULTS

G418 inhibition of W growth. Previous experiments have
shown that high levels of G418 (1 to 2 mg/ml) must be present for a substantial period of time (24 to 48 h) to inhibit the replication of mammalian cells and that different cell lines differ widely in their sensitivity to this drug (18) . Since VV macromolecular synthesis occurs within the cytoplasmic compartment of infected cells and utilizes the host cell translational apparatus (8) , it seemed likely that these considerations would also apply to G418 inhibition of viral growth. Therefore, the effect of increasing concentrations of G418 on the yield of VV progeny from one-step infections carried out on BSC-40 cell monolayers was assayed (Fig. 1) . VV replication was sensitive to G418-mediated inhibition, being reduced 95% by a concentration of 2 mg/ml. Under these conditions, VV plaque formation w abolished. The time of treatment required inhibit VV growth was also examined (Tabl the effects observed were not dramatic, there reduction of VV growth which correlated wi cells had been treated with G418, from 0 1 infection. Based on these results, the stand used for the rest of the experiments reported I at 2 mg/ml added 48 h before infection and ma concentration throughout the infection. Und tions, the cells appeared normal and VV r essentially blocked. Similar results were obi host cells. For example, a 48-h treatment of ] 2 mg of G418 per ml resulted in 97.3% inl growth.
Construction of VV:NEO recombinants. whether the inhibition of VV replication by overcome by the neomycin resistance gene rescue techniques were used to isolate VV containing this gene. Figure 2 shows the rec mids that were constructed to mobilize the ne VV genome. The neo gene from transposo inserted into the VV insertion vector pVVJ correct (--) and incorrect (+-) orientation rek 7.5Kd gene promoter, which is expressed bot] during infection (11) . The flanking VV DI allowed these chimeric genes to be recomi resident VV tk gene by transfecting them intc of VV-infected cells (submitted for publicati VV recombinants were detected and isola hybridization and several rounds of plaque pi genomic analysis of these recombinants is si
The pattern of VV DNA fragments gener showed that the 5.2-kilobase (kb) Sall M fragi wild-type DNA was replaced in the two (3) was (Fig. 3B) . In contrast, when labeled neo DNA was used as 5.1 in both the the probe, no hybridization to parental VV DNA or to the ative to the VV 0.6-kb fragment, which should contain only VV sequences, h early and late was detected, whereas the 5.8-kb band apparently contained NA sequences the neo gene (Fig. 3C ). The orientation of neo within the bined into the recombinants was determined by XhoI-RsaI double diges-) the cytoplasm tion. If the gene were in the correct orientation this would [on). Individual liberate a 469-base-pair fragment of neo, whereas in the Lted by plaque opposite orientation a 700-bp fragment would be generated urification. The (Fig. 2) . The data (Fig. 3D ) confirmed that isolated VV:NEO iown in Fig. 3 whereas VV:NEO formed almost the same number of _¢ plaques as on the control plate, although they were sli tl smaller. This would indicate that the progeny VV:NEO 05-virions were able to spread from cell to cell and overcome the G418-mediated inhibition in second-and third-generation infections. VV:O behaved identically to wild-type VV in these assays (data not shown).
Mechanism of G418 inhibition of W replication. G418 is an aminoglycoside antibiotic which inhibits eucaryotic protein mbinants. DNAs synthesis by interfering with 80S ribosome function (2). Thus 3 were restricted it was of interest to investigate the mechanism by which this sis (A). at the translational level or indirectly at the posttranslational level (i.e., cleavage). G418 enhancement of marker rescue efficiency. To ascertain whether G418 selection could be used during the initial marker rescue steps to raise the percentage of recombinants obtained, the following experiment was performed. The VV:NEO plasmid was transfected into recipient cells with and without G418, the progeny of the initial rescue were passaged one additional time (with and without drug selection), and the percentage of recombinant virions was determined by a combination of plaque assay and hybridization protocols. Having G418 present during either the marker rescue or amplification step resulted in a modest increase in the efficiency of marker rescue, twofold and fourfold, respectively (Table 3) . However, when the drug was present during both steps, a synergistic 70-fold increase in the percentage of recombinants was observed. DISCUSSION These experiments have demonstrated that the antibiotic G418 is an effective and potent inhibitor of VV replication in mammalian cells. When cell monolayers are treated for 48 h before infection with 2 mg of G418 per ml, the growth of VV is inhibited by 95 to 99% and the ability of the virus to form visible plaques is totally blocked. The G418-mediated inhibition is apparently due to a reduction in the expression of a subset of VV late genes. In any case, the inhibition can be overcome by introducing a bacterial neomycin resistance gene into the VV genome so that it is regulated and expressed by a VV promoter. Such a recombinant (VV:NEZ) is able to replicate, assemble, form plaques, and express its entire genetic program in the presence of high levels of G418.
This information should be of immediate consequence as far as using neo as a positive selectable marker to facilitate the selection and isolation of VV recombinants containing foreign genes of interest. There are at least two potential avenues to pursue. First, it is possible that the pVV5.1:NEt plasmid could be cotransfected into VV-infected cells along with another gene which is in a different VV insertion vector plasmid in the presence of G418. The second insertion vector could contain either similar or dissimilar flanking VV DNA sequences so long as they resulted in insertion in a nonessential region. Cells which are competent for DNA uptake should take up both plasmids. The neo gene will be expressed in those cells and allow a productive infection and concomitant marker rescue to occur. Conversely, VV which infect noncompetent cells will be unable to replicate in the presence of G418. This procedure would use the neo gene to convect other genes into the VV genome while reducing the background of wild-type VV replication. Convection procedures have previously been applied successfully in cellular transformation studies (5) and to temperature-sensitive VV mutants (9) . A second approach would be to construct dual-insertion vectors with the neo gene linked to a second gene. This latter approach would have the potential advantage of allowing VV recombinants to be selected directly after the marker rescue procedure. Any virus able to form plaques in the presence of G418 should contain the neo gene as well as the passenger gene of interest. Since neo is a bacterial gene and probably not significantly homologous to any VV DNA sequences, such insertion vectors could be tailored by virtue of their homologous VV DNA flanking sequences to insert the foreign gene in any nonessential region of the viral genome. Such plasmid constructions with a variety of VV promoters and assayable foreign genes are currently in progress. 
